Fragment-guided design of subnanomolar beta-lactamase inhibitors active in vivo - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Accéder directement au contenu
Article Dans Une Revue Proceedings of the National Academy of Sciences of the United States of America Année : 2012

Fragment-guided design of subnanomolar beta-lactamase inhibitors active in vivo

Résumé

Fragment-based design was used to guide derivatization of a lead series of beta-lactamase inhibitors that had heretofore resisted optimization for in vivo activity. X-ray structures of fragments overlaid with the lead suggested new, unanticipated functionality and points of attachment. Synthesis of three derivatives improved affinity over 20-fold and improved efficacy in cell culture. Crystal structures were consistent with the fragment-based design, enabling further optimization to a K-i of 50 pM, a 500-fold improvement that required the synthesis of only six derivatives. One of these, compound 5, was tested in mice. Whereas cefotaxime alone failed to cure mice infected with beta-lactamase-expressing Escherichia coli, 65% were cleared of infection when treated with a cefotaxime: 5 combination. Fragment complexes offer a path around design hurdles, even for advanced molecules; the series described here may provide leads to overcome beta-lactamase-based resistance, a key clinical challenge.

Dates et versions

hal-02650778 , version 1 (29-05-2020)

Identifiants

Citer

Oliv Eidam, Chiara Romagnoli, Guillaume Dalmasso, Sarah Barelier, Emilia Caselli, et al.. Fragment-guided design of subnanomolar beta-lactamase inhibitors active in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109 (43), pp.17448 - 17453. ⟨10.1073/pnas.1208337109⟩. ⟨hal-02650778⟩
16 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More